Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 4Breast 4Thoracic 3Gastrointestinal 2Plasma cell 1NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 60Lung Neoplasms 38Melanoma 22Ovarian Neoplasms 20Breast Neoplasms 18Mesothelioma, Malignant 13Colorectal Neoplasms 13Pancreatic Neoplasms 12Neoplasm Metastasis 12Small Cell Lung Carcinoma 11Triple Negative Breast Neoplasms 10Carcinoma, Renal Cell 10Neoplasms 9Mesothelioma 9Stomach Neoplasms 8Sarcoma 8Thymoma 7Carcinoma, Hepatocellular 7Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Merkel Cell 6Esophageal Neoplasms 5Carcinoma, Transitional Cell 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Sarcoma, Synovial 4Multiple Myeloma 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Ovarian Epithelial 4

Interventions

fludarabine 3aldesleukin 3Cyclophosphamide 3vedolizumab 2atezolizumab 2Riluzole 2LDP-02 2Infliximab 2Immunoglobulin G 2Fecal Microbiota Transplantation 2Disulfides 2CT-P13 2prednylidene 1pembrolizumab 1motexafin gadolinium 1deltacortene 1Tinzaparin 1Therapeutics 1Taste 1Standard of Care 1Radiotherapy 1Prednisone 1Practice Guidelines as Topic 1Loperamide 1Interleukin-2 1Immunotherapy 1Geriatric Assessment 1Fatty Acids, Omega-3 1Exercise 1Endoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Cyclophosphamide × Thoracic × Clear all
NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06253520 2026-05-08

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
210 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT04102436 2024-03-12

Non-Viral TCR Gene Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡